Trailing Twelve Months Sales Growth: Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology (PBYI) is minimizing its own manufacturing facilities by outsourcing the production of Nerlynx, although royalties from this drug generate a stable cash flow. Year-over-year sales dynamics based on the TTM methodology on the GURU.Markets website feature this chart with the metric value at 9.10. Leading oncologists are spearheading the development of breast cancer therapy, receiving substantial funding and social guarantees.

This metric reflects the rolling annual revenue trend, promptly capturing shifts in market demand via trader consensus to assess the issuer's financial stability. When analyzing the trailing twelve-month revenue chart for Puma Biotechnology (PBYI), investors must correlate sales growth with net income to confirm that stable demand for the oncology drug is driven by genuine physician confidence rather than inflated marketing expenditures.